|
Published by: Global Markets Direct
Published: Nov. 28, 2012 - 42 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Birch Pollen Allergy Overview
- Therapeutics Development
- An Overview of Pipeline Products for Birch Pollen Allergy
- Birch Pollen Allergy Therapeutics under Development by Companies
- Birch Pollen Allergy Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Birch Pollen Allergy Therapeutics – Products under Development by Companies
- Birch Pollen Allergy Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Birch Pollen Allergy Therapeutics Development
- ALK-Abello A/S
- Allergopharma Joachim Ganzer KG
- Circassia Holdings Ltd.
- ImVisioN Therapeutics AG
- Biomay AG
- Birch Pollen Allergy – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Birch Pollen Allergoid - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- AL-0206st - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ALK Birch Pollen Vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IVN-Birch - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BM-31 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ToleroMune Allergy T-Cell Vaccines - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Bet V 1AF1-Alum + Bet V 1AF2-Alum - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PL-102 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Birch Pollen Allergy Therapeutics - Dormant Products
- Birch Pollen Allergy – Product Development Milestones
- Featured News & Press Releases
- Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen
- Aug 31, 2010: Anergis's Ultra-Fast Treatment Against Birch Pollen Allergy Demonstrates Long Term Immunoregulatory Effect
- Jul 17, 2009: Anergis Reports Encouraging Seasonal Clinical Results With Birch Pollen Allergy Drug Candidate AllerT
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Birch Pollen Allergy, H2 2012
- Products under Development for Birch Pollen Allergy – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- ALK-Abello A/S, H2 2012
- Allergopharma Joachim Ganzer KG, H2 2012
- Circassia Holdings Ltd., H2 2012
- ImVisioN Therapeutics AG, H2 2012
- Biomay AG, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Birch Pollen Allergy Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Birch Pollen Allergy, H2 2012
- Products under Development for Birch Pollen Allergy – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractBirch Pollen Allergy – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Birch Pollen Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Birch Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy. Birch Pollen Allergy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Birch Pollen Allergy.
- A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Birch Pollen Allergy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
